

1 Vaginal Microbiota Transplantation (VMT) for treatment of vaginal 2 dysbiosis without the use of antibiotics – A Double-Blinded Randomized 3 Controlled Trial in healthy women with vaginal dysbiosis

4 **Authors and affiliations**

5 Tine Wrønding (1), Kilian Vomstein (1), Kevin DeLong (2), Agnete Troen Lundgaard (1), Sarah Mollerup (3), Brynjulf
6 Mortensen (2), Elleke F. Bosma (2), Ann Marie Hellerung (1), Emilie Vester Engel (1), Klara Dorte Wiil (1), Julie Elm
7 Heintz (3), Sofie Ingdam Halkjær (3), Luisa W Hugerth (6), Tanja Schlaikjær Hartwig (1), Andreas Munk Petersen (3,4,5),
8 Anne Bloch Thomsen (2), David Westergaard (1), Nina La Cour Freiesleben (1), Henrik Westh (3)(5), Johan E.T. van
9 Hylckama Vlieg (2), Laura M. Ensign PhD (2, 5) and Henriette Svarre Nielsen (1,5).

10

- 11 1. Department of Obstetrics and Gynecology, The Fertility Clinic, Copenhagen University Hospital, Hvidovre,
12 Denmark
- 13 2. Freya Biosciences Aps, Fruebjergvej 3, 2100 Copenhagen, Denmark
- 14 3. Department of Clinical Microbiology, Copenhagen University Hospital, Hvidovre, Denmark
- 15 4. Gastrounit, Medical Division, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark
- 16 5. Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen,
17 Copenhagen, Denmark
- 18 6. Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University,
19 Uppsala, Sweden
- 20 7. Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore,
21 MD 21231, USA; Department of Chemical & Biomolecular Engineering, Johns Hopkins University, Baltimore,
22 MD 21218, USA; Department of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of
23 Medicine, Baltimore, MD 21287, USA; Department of Pharmacology and Molecular Sciences, Johns Hopkins
24 University School of Medicine, Baltimore, MD 21287, USA; Departments of Gynecology and Obstetrics,
25 Infectious Diseases, and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA;
26 Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD 21218, USA.

27

28 Corresponding author: Henriette Svarre Nielsen, henriette.svarre.nielsen@regionh.dk

29

30 **Abstract:**

31 Here we describe the first double-blinded, randomized, placebo-controlled trial (RCT) on vaginal microbiota
32 transplantation (VMT) without antibiotics in women with *both* symptomatic and asymptomatic vaginal
33 dysbiosis. Forty-nine women were randomly assigned to VMT or placebo. The trial did not show a significant
34 conversion to our predefined *Lactobacillus*-dominated microbiome. However, in participants not initially
35 converting, antiseptic pretreatment before a subsequent VMT led to a 50% conversion rate, associated with
36 an anti-inflammatory shift in gene expression. Metagenomic sequencing and strain-level genetic analysis
37 confirmed donor engraftment in five of 10 women who showed microbiome conversion. Extensive
38 exploration of the microbiome, immune response and metadata revealed differences in baseline energy
39 metabolism in participants who later experienced donor engraftment. Treatments for vaginal dysbiosis are

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

40 urgently needed and given that VMT can lead to donor engraftment and change the vaginal immune profile,
41 future studies should focus on optimizing this treatment for various women's health diseases.

42 **Keywords:**

43 Vaginal dysbiosis, Vaginal Microbiota Transplantation, Antibiotic treatment, Antiseptic pretreatment,
44 Immunological changes, Recurrent BV, Randomized Controlled Trial

45 **Introduction**

46 A vaginal microbiome dominated by lactobacilli (*L. crispatus*, *L. gasseri*, *L. iners*, or *L. jensenii*) is associated
47 with reproductive tract health (1–3). The production of lactic acid by these bacteria lowers the vaginal pH,
48 typically to values below 4.5 (4). A more diverse vaginal microbiome dominated by other bacteria such as
49 *Gardnerella* spp., *Fannyhessea vaginae*, and *Prevotella* spp. is referred to as vaginal dysbiosis (1–3). Vaginal
50 dysbiosis is estimated to be prevalent in 16-52% of women depending on study population (5) and geographic
51 location (6,7) and is associated with a lower chance of conceiving in *in-vitro* fertilization (5), higher risk of
52 euploid pregnancy loss (8), and obstetric complications such as premature rupture of membranes and
53 preterm birth (9). Vaginal dysbiosis is lacking standardized diagnostic criteria and probiotics and antibiotics
54 are being tested for their efficacy in treating vaginal dysbiosis (1,10). Bacterial vaginosis (BV) is characterized
55 by an overgrowth of anaerobic bacteria, such as *Gardnerella vaginalis*, and a decrease in lactobacilli. BV is
56 diagnosed using Amsel criteria (10) or Nugent score (11), and is typically treated with antibiotics. Key
57 distinctions between BV and vaginal dysbiosis include the broader microbial imbalances in vaginal dysbiosis
58 versus the specific microbial shifts in BV, with diagnostic and treatment protocols tailored accordingly
59 (1,12,13). However, antibiotic treatment has some major drawbacks, including a recurrence rate of up to
60 60% within 12 months after treatment (12) due to high resistance rates to antibiotics (14–16). Also, orally
61 administered metronidazole and clindamycin can disturb the gut microbiome (17), while vaginally applied
62 antibiotics often result in subsequent vulvovaginal candidiasis (18).

63 To reduce recurrence rates after antibiotic treatment, a study from 2019 explored the use of vaginal
64 microbiota transplants (VMT) sourced from healthy donors with a *Lactobacillus*-dominated vaginal
65 microbiome. The study included five women with recurrent BV and four out of the five women showed
66 clinical remission after up to three cycles of combined antibiotic and VMT interventions (19). In a case-study,
67 our team successfully treated a woman with a complicated pregnancy history and severe symptomatic,
68 *Gardnerella*-dominated vaginal dysbiosis with VMT without antibiotic pretreatment and observed donor
69 strain engraftment (20). While these proof-of-concept studies provided promising results, the concept of
70 VMT has not been tested in a randomized placebo-controlled trial (RCT) setting. Here we present a RCT
71 testing VMT versus placebo in women with verified vaginal dysbiosis regardless of vaginal symptoms and test

72 antiseptic pretreatment prior to VMT. In a companion study by Bosma and Mortensen et al., VMT is tested
73 in asymptomatic women with vaginal dysbiosis using a different dosing regimen. Both studies aim to explore
74 the immunological changes in relation to changes in the vaginal microbiota.

75

76 Results

77

78 Randomized Controlled Trial

79 Between June 1st 2021 and June 2nd 2022, we screened 302 healthy women of whom 51 (16.9%) met all
80 eligibility criteria for participating in the study as a recipient (figure 1). Two of these women showed an
81 eubiotic microbiome at the baseline visit and were excluded from further participation. Therefore, 49 women
82 were randomly assigned to either VMT (n=37) or placebo (n=12) (saline water). The baseline characteristics
83 for recipients are shown in table 1. The microbiome composition at all visits is shown in figure 2. The diversity
84 in the vaginal microbiome in the VMT and the placebo group did not differ significantly at baseline. The most
85 abundant taxon were *Gardnerella* spp., in 80-82% of the recipients (figure 2B). The primary outcome of the
86 RCT trial was pre-defined as dysbiosis resolution (minimum of 70% total relative abundance of *Lactobacillus*
87 spp. and a combined proportion of *Gardnerella* spp., *F. vaginae*, and *Prevotella* spp. of <10%) at any timepoint
88 from first intervention to six month follow-up. After the first VMT, one out of 37 women (2.7%) in the VMT
89 group changed her microbiome from dysbiotic to eubiotic. In the placebo group, two out of 12 women
90 (15.4%) converted to eubiotic vaginal microbiome after the first intervention. We observed comparable rates
91 of dysbiosis resolution following each dosing cycle. At the three-month follow-up, six months after the first
92 intervention 11.4%, 4/35 in the VMT group and 37.3%, 3/11 in the placebo group had dysbiosis resolution.
93 We found no significant difference between women receiving VMT versus placebo, with a hazard ratio (HR)
94 of 0.71 (95% CI 0.18-2.76, p=0.64) (figure 3A). For the overall dysbiosis resolution counts see figure 3B.

95 Single nucleotide variant (SNV) analyses

96 SNV analyses were performed to evaluate if the converted microbiome in the VMT group was due to donor
97 strain engraftment or spontaneous conversion. In two of the four women with dysbiosis resolution in the
98 VMT group, we could identify donor strain engraftment (figure 4A and 4B). The two participants with donor
99 strain engraftment also were the only ones of the converted who persistently showed a eubiotic microbiome
100 composition 199 days after VMT (figure 4A and 4B).

101 Adverse events

102 There were no reports of serious adverse events (SAEs), and none of the adverse events, which was 15 (40.5
103 %) in the VMT group and 5 (41%) in the placebo group resulted in premature termination of study
104 participation. One participant became pregnant during the study period and subsequently dropped out. The
105 pregnancy was unrelated to the treatment. Another participant was diagnosed with HPV which had not been
106 detected at baseline. This HPV strain was not found in the VMT used in the recipient (see supplementary
107 table 4).

108 **Flow cytometry analysis**

109 Flow cytometry analysis was conducted to evaluate immune cell populations in both peripheral and
110 menstrual blood in relation to VMT and microbiome conversion. The cell types analyzed included CD56+
111 natural killer (NK) cells, with subsets CD56^{bright}CD16^{dim} and CD56^{dim}CD16^{bright}, along with their subtypes
112 NKG2A, NKG2D, and NKp46. Additionally, T-cell populations were assessed, including CD8⁺ and CD4⁺ T-cells,
113 regulatory T-cells (Tregs), and T-helper (TH) subsets: TH1, TH2, TH17, TH22. Despite this comprehensive
114 analysis, no significant differences in immune cell populations were observed, in relation to the VMT or
115 dysbiosis resolution – neither in peripheral blood nor in menstrual blood. Results of the flow cytometry
116 analyses are shown in supplementary figure 1a-g and supplementary figure 2a-g.

117 **Antiseptic pretreatment sub-study**

118 We reasoned that a decrease in the load of vaginal dysbiosis associated bacteria may facilitate the ability of
119 the donor microbiome to engraft and therefore decided to evaluate the effect of antiseptic pretreatment
120 prior to an additional VMT in an open-label extension in refractory participants. We decided to use the
121 antiseptic chlorhexidine, as previous studies have shown its efficacy in decreasing bacterial load (21,22). 27
122 recipients were refractory to primary treatment (both VMT and placebo) and met the eligibility criteria for
123 and accepted participation in the open-label extension of antiseptic pretreatment. Ten women received
124 pretreatment with antiseptic (Chlorhexidine-Cetrimide 0.2%-0.1%) followed by VMT. Five of ten women
125 (50%) displayed successful conversion of their vaginal microbiome towards a *Lactobacillus*-dominated state
126 at two weeks after treatment. Ten women received a pretreatment with saline water followed by VMT, and
127 seven women received a treatment with antiseptic without VMT. None of these 17 women showed a
128 conversion towards a *Lactobacillus*-dominated microbiome two weeks after treatment. Therefore, antiseptic
129 pretreatment followed by VMT was shown to have a significantly higher conversion rate than saline
130 pretreatment followed by VMT with an odds ratio (OR) of 21 (95% CI 1.83;2956, Bonferroni adj. p-value =
131 0.033) (figure 5A). SNV analysis of the five women with successful conversion towards a *Lactobacillus*-
132 dominated microbiome showed that at least three of five women showed donor strain engraftment (figure

133 5B). One did not have enough reads for SNV analysis and one did not show donor engraftment, but
134 conversion.

135 **KEGG functional analysis of converters and engrafters in both the RCT and antiseptic pre-treatment study**

136 When looking into features, that differed between engrafters and converters, a higher abundance of *L.*
137 *crispatus* was observed post VMT in recipients with donor engraftment compared to recipients converting
138 their microbiome without donor engraftment indicating a stronger shift towards *lactobacillus* dominance
139 (engrafted: 71-100%, mean 90.1%; not engrafted: 0-100%, mean 32.3%; $p = 0.09$ after multiple testing
140 adjustment) (supplementary figure 3). Furthermore, functional KEGG analysis of pre-conversion samples
141 show that three pentose-phosphate pathways (PPP) (PENTOSE-P-PWY, NONOXIPENT-PWY, PWY-8178) and
142 one glycolysis pathway (PWY-5484) in energy metabolism were less abundant in the microbiome of the group
143 with donor strain engraftment than in the group who just converted (supplementary figure 3). These
144 pathways were not associated to any particular bacterial species (23).

145 **Transcriptomics**

146 Using NanoString transcriptomics on cervico vaginal secretion (CVS) in the antiseptic extension study, we
147 identified 130 out of 649 genes that were differentially expressed between the group with successful
148 conversion of the microbiome towards eubiosis after antiseptic + VMT ($n=4$) when compared to the group
149 that did not convert ($n=5$) (figure 5C). The group with successful conversion showed significant
150 downregulation in the expression of CASP-10, IL-32, CXCL2, and CD8b. These findings indicate alterations in
151 the gene expression profile post-VMT, with decreased expression levels in genes associated with apoptotic
152 processes (CASP-10), inflammatory response (IL-32 and CXCL2), and cytotoxic T cell activity (CD8b). In
153 addition to the downregulation of certain genes post-VMT, the analysis also revealed significant upregulation
154 in other key genes. Notably, there was an increase in the expression levels of IL-18, a cytokine involved in
155 immune response modulation, and LGALS3, which plays a role in cell adhesion and modulation of cell-cell
156 interactions. Further, using principal component analysis (PCA) on the ratio between pre- and post-VMT
157 expression, we found a distinct clustering of the two groups at PC1 and PC2 (Supplementary figure 4).
158 However, we only observed this effect in three out of four individuals who converted their microbiome
159 (Supplementary figure 5). Based on these analyses, we see distinct changes on a molecular level in response
160 to conversion from dysbiosis to eubiosis after treatment with local antiseptic followed by VMT.

161 **Discussion**

162 Building upon the pioneering landmark study on the concept of VMT (19), our study, alongside the
163 accompanying paper by Bosma and Mortensen et al., represents the first RCT to evaluate the efficacy of VMT

164 in women with both symptomatic and asymptomatic vaginal dysbiosis in up to three menstrual cycles
165 without prior antibiotic treatment. We could not identify a significant effect of a VMT when given as a single
166 dose per menstrual cycle and without any form of pretreatment. There are, however, two aspects of note:
167 a) the donor strain engraftment in two women who shifted to *Lactobacillus*-dominance was persistent up to
168 the last follow up after 199 days. b) in an open-label extension investigating the effect of antiseptic
169 pretreatment, we showed a significantly higher conversion rate in women treated with the antiseptic + VMT
170 than with antiseptic or VMT alone. Notably, this was in participants who had failed to respond to the
171 treatment in the initial part of the study. Moreover, most women who converted after antiseptic + VMT also
172 showed donor strain engraftment. These first results underscore the potential of VMT to facilitate the
173 engraftment of a *Lactobacillus*-dominated microbiome and thereby resolve vaginal dysbiosis in some
174 recipients. The persistent donor strain engraftment observed supports the conclusion that these were
175 genuine treatment-induced changes rather than spontaneous conversions. In a study previously published
176 by our group, we reported sustained donor strain engraftment for 430 days after VMT without pretreatment
177 in a woman with vaginal dysbiosis and a history of recurrent late pregnancy losses (20). In that study, we
178 performed donor selection based on the ability of the bacteria in donor CVS to inhibit the growth of dysbiosis-
179 associated bacteria in the patient using a plate diffusion assay. This was not performed in this study but could
180 potentially have increased success rates.

181 The parallel performed trial of Bosma and Mortensen et al. in a recipient population with asymptomatic
182 vaginal dysbiosis found VMT to be more successful than demonstrated here. Of note, in that study the
183 recipients received a VMT on three consecutive days and the definition of when a VMT was successful was
184 defined as the change in overall vaginal lactobacilli (combination of *L. crispatus*, *L. iners*, *L. gasseri*, and *L.*
185 *jensenii*) by relative abundance and not with a predefined 70% relative abundance of vaginal lactobacilli
186 (combination of *L. crispatus*, *L. iners*, *L. gasseri*, and *L. jensenii*) and a combined proportion of *Gardnerella*
187 *spp.*, *F. vaginae*, and *Prevotella spp.* of <10%, as in this study.

188 The observed changes in gene expression after dysbiosis resolution, including the upregulation of IL-18 and
189 LGALS3 and the downregulation of CASP-10, IL-32, CXCL2, and CD8b, provide insights into the immunological
190 impact of VMT. The upregulation of IL-18 and LGALS3 suggests enhanced immune surveillance and
191 integration of the new microbiota (24,25), while the downregulation of CASP-10, IL-32, CXCL2, and CD8b
192 indicates a shift towards reduced inflammation and cytotoxicity (26–28). These findings highlight VMT's
193 potential as a modulator of local immune responses, fostering a stable vaginal microbiome, but should be
194 interpreted with caution due to the small sample size.

195 In contrast to the gene expression changes observed post-VMT, our flow cytometric analysis of both
196 peripheral and menstrual blood revealed no significant differences in the systemic and local immune cell
197 populations. This absence of detectable changes on a cellular level could suggest that the immunological
198 impact of VMT, at least in the context of circulating immune cells, might be more subtle or localized. These
199 findings although based on a limited number of individuals highlight the complex immune responses to VMT
200 and the need for multifaceted research. Further studies on localized tissue responses and longitudinal
201 immune monitoring could deepen our understanding of immune dynamics following VMT.

202 Our study aimed to identify patterns or characteristics of recipients exhibiting donor strain engraftment and
203 to determine if specific donor VMTs were more effective. Taxonomically, recipients with donor engraftment
204 showed significantly higher levels of *L. crispatus* post-VMT treatment compared to those in the conversion
205 group, suggesting a more substantial shift towards eubiosis. Additionally, functional analysis indicated that
206 recipients with confirmed donor strain engraftment displayed distinct differences in genes associated with
207 energy metabolism, particularly the pentose phosphate pathway (PPP) and glycolysis. While direct research
208 linking these pathways to vaginal health is limited, PPP is crucial for NADPH production, protecting vaginal
209 epithelial cells from oxidative damage, and glycolysis supports the energy needs of these cells, maintaining
210 an optimal environment for beneficial bacteria, primarily lactobacilli (29,30). Since these pathways were
211 more abundant in the subjects that converted without engraftment (in other words, without direct support
212 from the VMT), it could be speculated that they had a healthier baseline state, allowing spontaneous
213 conversion. In contrast, the recipients with donor strain engraftment had a more dysbiotic state at baseline
214 but converted to an even more eubiotic state with a higher *L. crispatus* abundance.

215 Interesting, when performing VMTs in the antiseptic pretreatment study, we found that some VMTs that did
216 not lead to resolution in the RCT proved to be successful after pretreatment. Overall, we did not observe a
217 clear 'super donor' effect, but engraftment seems to be determined by interactions between donor and
218 recipient microbiomes. Future studies including a higher number of subjects are required to reveal the
219 mechanisms determining engraftment of donor microbiomes.

220 We postulate that the high conversion rate after antiseptic pretreatment is due to a combination of bacterial
221 load reduction and removal or disruption of the vaginal biofilm, which especially *G. vaginalis* is known to
222 produce (31,32). Bacteria within biofilms resist elimination by the immune system and are not completely
223 eradicated by antibiotics, potentially resulting in persistence or recurrence (33–36). It is plausible that the
224 antiseptic Chlorhexidine-Cetrimide weakened the biofilm in participants. This process likely enabled the
225 establishment of a healthy vaginal environment through VMT.

226 In contrast to a treatment with a single isolated lactobacillus strain, the VMT contains the whole community
227 of multiple strains of lactobacilli, bacteriophages, proteins, cytokines, lipids, antimicrobial peptides that
228 before transplantation formed a stable colonization in the donor. Transplantation of the whole community
229 possibly seems to be key to a lasting engraftment as shown in patients with donor strain engraftment. Among
230 other things, these factors include already resident vaginal bacteria, glycogen and lactic acid (37–39).

231 While this study marks a significant step forward in exploring VMT as a treatment for vaginal dysbiosis, it also
232 highlights areas for optimization of efficacy. The lack of significant effects without pretreatment with a single
233 dose in our recipient population suggests that factors such as dosing, and donor selection play a crucial role
234 in the efficacy of VMT as a stand-alone treatment. Future studies should consider these variables more
235 closely, potentially also exploring personalized approaches to donor matching when used without antibiotics
236 or antiseptic pretreatment. These refinements could be key in maximizing the therapeutic potential of VMT,
237 making it a more effective and reliable treatment option for vaginal dysbiosis. Replacing dysbiosis-associated
238 bacteria with a *Lactobacillus*-dominated vaginal community and resetting the immunological tone of the
239 reproductive tract could significantly influence a broad spectrum of reproductive and women's health
240 conditions.

241 **Strengths and limitations**

242 The clinical trial being conducted in Denmark and reflecting the ethnic makeup of this population limits the
243 generalizability of the findings to other populations, where the frequency of BV has previously been reported
244 to be higher than observed in this study (7,40). Although being the largest VMT study we have limited
245 statistical power in flow cytometry and antiseptic pretreatment sub-studies. Additionally, the post-hoc
246 analysis comparing engrafters versus non-engrafters and their characteristics would require a larger sample
247 size to draw robust conclusions. Overall, the studies presented here highlight crucial fundamental insights
248 into the benefits of VMT and establish essential methodological foundations to support future large-scale
249 intervention studies for various conditions and diseases affecting the female reproductive tract.

250 **Methods**

251 **Study design**

252 This double-blinded randomized controlled-trial of VMT in women with vaginal dysbiosis, was conducted at
253 Copenhagen University Hospital, Hvidovre, Denmark between June 2021-March 2023.

254 **Primary outcome:**

- 255 1. Conversion to a *Lactobacillus*-dominated (eubiotic) microbiome following VMT treatment, given up
256 to three times without antibiotic pretreatment [Time Frame: up to six months from transplantation]

257 Secondary outcomes:

- 258 1. Conversion to a *Lactobacillus*-dominated (eubiotic) microbiome following one VMT treatment [Time
259 Frame: two weeks from transplantation]
- 260 2. Identification of donor microbiome in recipients
- 261 3. T- and NK-Cell changes in peripheral and menstrual blood after VMT compared to baseline using flow
262 cytometry
- 263 4. In treatment-refractory participants, conversion rate two weeks after antiseptic pretreatment
264 followed by an additional VMT when an antiseptic vaginal wash is performed immediately before the
265 VMT.

266 Participant recruitment

267 Women were recruited through social media, internally at the study site at Copenhagen University Hospital,
268 Hvidovre, and via posters at different educational institutions in the Copenhagen area.

269 The overall inclusion criteria for study participation were women between the age of 18-40 years who
270 considered themselves healthy, were premenopausal and not pregnant (see complete list of in- and exclusion
271 criteria in supplementary table 3). Participants were further screened and stratified into donors and
272 recipients. A pre-screening questionnaire was developed, in which participating women answered detailed
273 questions such as personal anamnesis, family medical history, life-style factors, sexual history and behavior,
274 contraceptive, and vaginal product usage.

275 Upon agreeing to participate, participants were asked to come to the study site on their cycle day 10±2 (or
276 any day in case of amenorrhea due to hormonal contraceptives), where they received further information
277 about the study in person, signed the informed consent form and self-collected a vaginal swab sample.

278 *Vaginal microbiome collection and stratification for donors and recipients*

279 Participants were instructed to sample 5-6 cm into the vagina and to ensure that the swab would not touch
280 other body parts or surfaces. For clinical sampling, Zymo Collection Swab, 80XX (Zymo research, California
281 US) swabs were used and stored in COPAN (Brescia, Italy) containers. See supplementary materials and
282 methods for details on vaginal microbiome analysis.

283 After this first screening and based on the sequencing analysis of the vaginal microbiome participants were
284 divided into two groups:

- 285 • Potential donors: a vaginal microbiome consisting of >80% relative abundance of vaginal
286 *Lactobacillus* spp. (*L. crispatus*, *L. jensenii*, *L. gasseri*, *L. iners*) and <5% relative abundance of the
287 following vaginal dysbiosis-associated bacteria (*Gardnerella* spp., *F. vaginae* and *Prevotella* spp.),
288 • Potential recipients: <10% total relative abundance of *Lactobacillus* spp., and >20% relative
289 abundance of *Gardnerella* spp., *F. vaginae* and *Prevotella* spp.

290 Participants were provided a window of 40 days to attend the second scheduled visit according to the study
291 protocol. During this visit, eligible donors and recipients underwent a comprehensive medical and
292 gynecological assessment. The exam included vaginal inspection, as well as a vaginal ultrasound scan, a
293 general health check including auscultation of heart and lungs, body weight, heart rate and blood pressure
294 measurements. Standard diagnostic blood and vaginal swab tests were conducted to evaluate the presence
295 of various pathogens and conditions, including human immunodeficiency virus (HIV), Hepatitis A/B/C,
296 cytomegalovirus (CMV), and herpes simplex virus (HSV) 1/2 (for a comprehensive list, see supplementary
297 figure 6a & 6b and supplementary tables 1 & 2).

298 [Intervention procedure in RCT](#)

299 Recipients needed to be willing to receive up to three VMTs dosed as single dosage once per menstrual cycle,
300 and to refrain from using intravaginal products and avoid activities like pool and bathtub usage. Additionally,
301 eligible recipients were also asked to refrain from vaginal and anal intercourse during the study period, unless
302 using condoms.

303 Exclusion criteria for recipients were documented disorders such as HIV, or if testing positive for HIV,
304 chlamydia, *Mycoplasma genitalium*, trichomonas or having a positive pregnancy test based on urine human
305 chorionic gonadotropin (HCG) at the second screening visit. See supplementary table 3 for further exclusion
306 criteria.

307 [Adverse events \(AE\)](#)

308 AE was defined as worsening of vaginal symptoms reported by the participants throughout the 6 months
309 study period, serological (HIV, Hepatitis A/B/C, CMV, CRP), sexually transmitted infections (*Mycoplasma*,
310 chlamydia, trichomonas, *Neisseria gonorrhoea*, HSV 1/2) and pregnancy. Aliquots of each donor transplant
311 were stored for testing in case of the AE potentially being related to the donor transplant.

312 [Randomization](#)

313 At the second visit, participants were randomized to receive the active treatment or placebo in a ratio of 3:1.
314 The randomization was done by the collaborating partner Freya Biosciences ApS (Copenhagen, Denmark),
315 using a computerized randomization program (Sealed Envelope™ Ltd, London, England). We used block

316 randomization with each block consisting of n=4 participants to ensure balanced allocation across treatment
317 groups.

318 Procedure

319 For comprehensive details on donor participant recruitment, as well as sample collection, processing,
320 analysis, and the characterization methods used for both donor and recipient samples see supplementary
321 materials and methods as well as supplementary table 3.

322 Study visits

323 Women who met the criteria for recipients at the initial screening and successfully met the additional
324 inclusion and exclusion criteria at the second visit were considered suitable as recipients. After the second
325 screening visit, a personalized calendar of future appointments was established based on the participants'
326 menstrual cycle.

327 The women were seen every 14 days. On menstrual cycle day (CD) 10 ± 2 days, they received the VMT or
328 placebo (see supplemental materials and methods). On CD 24 ± 2 in each menstrual cycle they came into the
329 clinic for a general health check-up, self-performed vaginal swab test, urine test and CVS samples which were
330 collected with a single-use menstrual disc. If recipients had amenorrhea due to hormonal contraceptives, a
331 cycle of 28 days was calculated, and visits planned accordingly.

332 To facilitate continuous monitoring, an online self-reported questionnaire was implemented. This
333 questionnaire was designed to be completed by recipients one day before each visit. It covered aspects such
334 as recent menstruation, vaginal discharge, sexual activity, condom use, and any new medications or relevant
335 information such as potential side-effects from the treatment.

336 Definition of dysbiosis resolution

337 Dysbiosis resolution was defined as a minimum of 70% total relative abundance of *Lactobacillus* spp. and a
338 combined proportion of *Gardnerella* spp., *F. vaginae*, and *Prevotella* spp. of <10%, by shotgun metagenomic
339 sequencing of a vaginal sample.

340 In total, recipients came into the clinic for nine visits, which could involve up to three VMTs, depending on
341 the success and timing of dysbiosis resolution. Upon dysbiosis resolution, the next scheduled appointment
342 for VMT was changed to a general check-up visit (see supplementary table 2 and supplementary figure 6b).
343 After the third cycle, and therefore final VMT, recipients returned for a follow-up visit after one and three
344 months. Further information on study visits for recipients is provided in supplementary table 2 and
345 supplementary figure 6b.

346 Flow cytometry

347 The first 24 participants with regular menstruation were asked to participate in the flow cytometry study.
348 The participants collected their menstrual blood for the first 48 hours of menstruation for flow cytometry
349 immune cell analysis of menstrual and peripheral blood. There were two timepoints of collection: The first
350 timepoint before the first VMT and a second timepoint after the follow-up 2 visit for the whole population.
351 Thereby, comparing participants with and without conversion of their microbiome (see supplementary table
352 2 and supplementary figure 7). For further information on cell isolation and procedure and analysis of isolated
353 lymphocytes, see the supplementary materials and methods flowcytometry section.

354 Antiseptic pretreatment

355 Recipients who did not meet the criteria for successful dysbiosis resolution after three single-dose VMTs over
356 three menstrual cycles were invited at the 3-month follow-up visit to participate in an open-label extension
357 of the RCT. Participants were randomly assigned to one of three treatment groups: 1) pretreatment with
358 Chlorhexidine-Cetrimide 0.2%-0.1%, followed by saline, followed by VMT, 2) pretreatment with saline
359 followed by VMT, 3) pretreatment with Chlorhexidine-Cetrimide 0.2% - 0,1% followed by saline and no VMT.

360 Each participant was scheduled for two visits: The initial visit was planned for CD 10±2, and consisted of a
361 general health-check and collection of biobank samples (see supplementary table 1b and supplementary
362 figure 8). For a description of procedure in the three treatment groups see supplementary material and
363 methods Procedure in the three treatment groups in the open-label extension section.

364 On CD 24±2, participants had a general health check and self-collected vaginal swab, urine, and CVS samples.
365 Vaginal swab samples were tested for *Chlamydia trachomatis*, *N. gonorrhoea*, *Trichomonas vaginalis*, *M.*
366 *genitalium*, group A, B, C & G *Streptococcus*, HSV 1/2 and *Candida* spp. Additionally, a gynecological
367 examination and ultrasound scan were performed and potential side effects, if any, were registered. For
368 further information on the antiseptic pretreatment see table 2 and figure 4 in supplementary materials and
369 methods. To identify changes in the immunological response at a transcriptional level, CVS was collected at
370 each visit and analyzed using the NanoString nCounter Human Immunology V2 Panel (see supplementary
371 materials and methods transcriptomic section for details).

372 Statistical analysis

373 Sample size calculation was based on results from the only existing intervention study on VMT, which
374 reported an 80% remission rate of BV (19). A 3:1 randomization was chosen to balance the considerations of
375 randomized design while optimizing the number of VMT treatments, yielding for a more robust and nuanced
376 understanding of its efficacy and risks.

377 Using these parameters and aiming for 80% statistical power to detect a significant difference ($p < 0.05$), our
378 sample size calculation indicated that a total of 48 participants (36 recipients in the active treatment arm and
379 12 in the placebo arm) were required.

380 We estimated that it would be necessary to screen 300-350 women to find 25 donors and 48 recipients, given
381 that 16-20% of Danish women of fertile age have been shown to have vaginal dysbiosis (5).

382 For demographic data, counts with percentages and means with standard deviations are reported. For
383 primary and secondary outcomes, Fisher's exact test was used for odds ratios, confidence interval and p-
384 values. We used unadjusted Kaplan-Meier curves and the log rank test to compare survival patterns by VMT
385 and placebo groups. All analysis was conducted in R (v. 4.3.0)

386 Fisher's exact test was used to determine the independence between the three groups in the antiseptic
387 pretreatment study. Group-by-group comparisons were conducted by Firth logistic regression for small
388 sample analysis using the logist package in R (v. 1.26.0). P-values were adjusted using Bonferroni correction.

389 The primary outcome was based on Intention To Treat (ITT). Since all participants followed the treatment
390 group they were assigned at randomization a per protocol analysis was not performed.

391 See supplementary materials and methods for details on microbiome and flow cytometry statistical data as
392 well as transcriptomic statistical data.

393 No data monitoring committee was assigned to this study.

394 [Legal and ethics statements](#)

395 The Randomized Controlled Trial study protocol was approved by the Danish ethical committee of the capital
396 region of Denmark (Journal-nr.: H-20068230) on the 16th of March 2021 and the Danish Data Protection
397 Agency (Pactius): P-2020-1080. The Randomized Controlled Trial was reported on ClinicalTrials.gov Identifier:
398 NCT04855006.

399 Three amendments were added to the study protocol: first, adding rectal swab collection (approved by the
400 Danish ethical Committee of the capital region of Denmark on the 15th of June 2021), second, sub-study
401 using flow cytometry to study immunological cells in peripheral and menstrual blood (approved by the
402 Danish ethical Committee of the capital region of Denmark on the 6th of December 2021) and third, a sub-
403 study of the impact of antiseptic pretreatment to the participants who did not meet the criteria for successful
404 VMT (approved by the Danish ethical Committee of the capital region of Denmark on the 17th of May 2022).

405 All research was conducted according to the Declaration of Helsinki and all participants provided written
406 informed consent.

407 **Other information**

408 **Data availability statement**

409 The datasets generated during and/or analyzed during the current study are available from the
410 corresponding author on reasonable request.

411 **Funding**

412 The study was partially funded (i.e., analysis costs) by Freya Biosciences Aps, Fruebjergvej, 2100 Copenhagen,
413 Denmark.

414 **Conflict of interest**

415 Elleke F. Bosma, Brynjulf Mortensen, Kevin DeLong, and Johan E.T. van Hylckama Vlieg are employees of
416 Freya Biosciences, ApS. Johan E.T. van Hylckama Vlieg, Laura M. Ensign, and Anne Bloch Thomsen are co-
417 founders and shareholders of Freya Biosciences, ApS. Laura M. Ensign is a co-inventor on patents and patent
418 applications in the area of microbial transplantation. Laura M. Ensign's arrangements have been reviewed
419 and approved by the Johns Hopkins University in accordance with its conflict-of-interest policies. All other
420 authors declare that they have no competing interests.

421 **Contributions**

422 Designed the study:

423 Henriette Svarre Nielsen, Tine Wrønding, Brynjulf Mortensen, Laura M. Ensign, Johan E.T. van Hylckama Vlieg
424 Kilian Vomstein and Nina La Cour Freiesleben

425 Participant recruitment, clinical performance and sampling:

426 Donors:

427 Elleke F. Bosma, Brynjulf Mortensen, Tine Wrønding, Ann Marie Hellerung, Klara Dorte Wiil, Emilie Vester
428 Engel and Kilian Vomstein

429 Recipients:

430 Tine Wrønding, Ann Marie Hellerung, Klara Dorte Wiil, Emilie Vester Engel and Kilian Vomstein

431 Wrote first version of the manuscript:

432 Tine Wrønding, Kilian Vomstein and Henriette Svarre Nielsen.

433 Revising the manuscript critically for important intellectual content:

434 Tine Wrønding, Kilian Vomstein, Henriette Svarre Nielsen, Elleke F. Bosma, Brynjulf Mortensen, Henrik
435 Westh, Julie Elm Heintz, Sara Mollerup, Laura M. Ensign, Kevin DeLong, Johan van Hylckama Vlieg, Anne Bloch
436 Thomsen, Andreas Munk Petersen, Ann Marie Hellerung, Klara Dorte Wiil, Emilie Vester Engel, Sofie Ingdam
437 Halkjær, Tanja Schlaikjær Hartwig, Agnete Troen Lundgaard, David Westergaard, Nina La Cour Freiesleben, Luisa
438 W. Hugerth

439 Performed the vaginal microbiome analysis and bioinformatics:

440 Julie Elm Heintz, Sarah Mollerup, Agnete Troen Lundgaard, David Westergaard, Kevin DeLong, Henrik Westh,
441 Andreas Munk Petersen and Luisa W. Hugerth

442 All authors made substantial contributions to the study set-up, data interpretation and manuscript revision.

443 All authors approved the final manuscript before publication.

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459 **References**

- 460 1. Coudray MS, Madhivanan P. Bacterial vaginosis-A brief synopsis of the literature. *Eur J Obstet*
461 *Gynecol Reprod Biol.* 2020 Feb;245:143–8.
- 462 2. Serrano MG, Parikh HI, Brooks JP, Edwards DJ, Arodz TJ, Edupuganti L, et al. Racioethnic diversity in
463 the dynamics of the vaginal microbiome during pregnancy. *Nat Med.* 2019;25(6):1001–11.
- 464 3. Cheng L, Norenhag J, Hu YOO, Brusselaers N, Fransson E, Ährlund-Richter A, et al. Vaginal microbiota
465 and human papillomavirus infection among young Swedish women. *NPJ biofilms microbiomes.*
466 2020;6(1):39.
- 467 4. Danielsson D, Teigen PK, Moi H. The genital econiche: focus on microbiota and bacterial vaginosis.
468 *Ann N Y Acad Sci.* 2011 Aug;1230(1):48–58.
- 469 5. Haahr T, Zacho J, Bräuner M, Shathmigha K, Skov Jensen J, Humaidan P. Reproductive outcome of
470 patients undergoing in vitro fertilisation treatment and diagnosed with bacterial vaginosis or
471 abnormal vaginal microbiota: a systematic PRISMA review and meta-analysis. *BJOG.* 2019
472 Jan;126(2):200–7.
- 473 6. Kenyon C, Colebunders R, Crucitti T. The global epidemiology of bacterial vaginosis: a systematic
474 review. *Am J Obstet Gynecol.* 2013 Dec;209(6):505–23.
- 475 7. Peebles K, Velloza J, Balkus JE, McClelland RS, Barnabas R V. High Global Burden and Costs of
476 Bacterial Vaginosis: A Systematic Review and Meta-Analysis. *Sex Transm Dis.* 2019 May;46(5):304–
477 11.
- 478 8. Grewal K, Lee YS, Smith A, Brosens JJ, Bourne T, Al-Memar M, et al. Chromosomally normal
479 miscarriage is associated with vaginal dysbiosis and local inflammation. *BMC Med.* 2022 Dec
480 28;20(1):38.
- 481 9. Juliana NCA, Suiters MJM, Al-Nasiry S, Morr  SA, Peters RPH, Ambrosino E. The Association Between
482 Vaginal Microbiota Dysbiosis, Bacterial Vaginosis, and Aerobic Vaginitis, and Adverse Pregnancy
483 Outcomes of Women Living in Sub-Saharan Africa: A Systematic Review. *Front Public Heal.* 2020 Dec
484 10;8.
- 485 10. Spiegel CA, Amsel R, Holmes KK. Diagnosis of bacterial vaginosis by direct gram stain of vaginal fluid.
486 *J Clin Microbiol.* 1983 Jul;18(1):170–7.
- 487 11. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a

- 488 standardized method of gram stain interpretation. *J Clin Microbiol.* 1991 Feb;29(2):297–301.
- 489 12. Bradshaw CS, Morton AN, Hocking J, Garland SM, Morris MB, Moss LM, et al. High recurrence rates
490 of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors
491 associated with recurrence. *J Infect Dis.* 2006 Jun 1;193(11):1478–86.
- 492 13. Joesoef MR, Schmid GP, Hillier SL. Bacterial vaginosis: review of treatment options and potential
493 clinical indications for therapy. *Clin Infect Dis.* 1999 Jan;28 Suppl 1:S57-65.
- 494 14. Schuyler JA, Mordechai E, Adelson ME, Sobel JD, Gyax SE, Hilbert DW. Identification of intrinsically
495 metronidazole-resistant clades of *Gardnerella vaginalis*. *Diagn Microbiol Infect Dis.* 2016
496 Jan;84(1):1–3.
- 497 15. Faught BM, Reyes S. Characterization and Treatment of Recurrent Bacterial Vaginosis. *J Women’s*
498 *Heal.* 2019 Sep 1;28(9):1218–26.
- 499 16. Ferris MJ, Masztal A, Aldridge KE, Fortenberry JD, Fidel PL, Martin DH. Association of *Atopobium*
500 *vaginae*, a recently described metronidazole resistant anaerobe, with bacterial vaginosis. *BMC Infect*
501 *Dis.* 2004 Feb 13;4:5.
- 502 17. Zimmermann P, Curtis N. The effect of antibiotics on the composition of the intestinal microbiota - a
503 systematic review. *J Infect.* 2019;79(6):471–89.
- 504 18. Shukla A, Sobel JD. Vulvovaginitis Caused by *Candida* Species Following Antibiotic Exposure. *Curr*
505 *Infect Dis Rep.* 2019 Nov 9;21(11):44.
- 506 19. Lev-Sagie A, Goldman-Wohl D, Cohen Y, Dori-Bachash M, Leshem A, Mor U, et al. Vaginal
507 microbiome transplantation in women with intractable bacterial vaginosis. *Nat Med [Internet].* 2019
508 Oct 1 [cited 2020 Aug 11];25(10):1500–4. Available from:
509 <https://pubmed.ncbi.nlm.nih.gov/31591599/>
- 510 20. Wrønding T, Vomstein K, Bosma EF, Mortensen B, Westh H, Heintz JE, et al. Antibiotic-free vaginal
511 microbiota transplant with donor engraftment, dysbiosis resolution and live birth after recurrent
512 pregnancy loss: a proof of concept case study. *eClinicalMedicine.* 2023 Jul;61:102070.
- 513 21. Łaniewski P, Smith G, Crossley P, Farland L V., Mahnert ND, Herbst-Kralovetz MM. Impact of
514 chlorhexidine and povidone-iodine antiseptic solutions on the cervicovaginal microenvironment
515 during laparoscopic hysterectomies: a pilot study. *npj Women’s Heal.* 2024 May 18;2(1):16.
- 516 22. Petersen E, Weissenbacher E, Hengst P, Spitzbart H, Wolfgang W, Wolff F, et al. Local Treatment of

- 517 Vaginal Infections of Varying Etiology with Dequalinium Chloride or Povidone Iodine.
518 *Arzneimittelforschung*. 2011 Dec 26;52(09):706–15.
- 519 23. Keller MA, Turchyn A V, Ralser M. Non-enzymatic glycolysis and pentose phosphate pathway-like
520 reactions in a plausible <sc>A</sc> rchean ocean. *Mol Syst Biol*. 2014 Apr 25;10(4).
- 521 24. Yamada SM, Pontillo A. The genetics behind inflammasome regulation. *Mol Immunol*. 2022
522 May;145:27–42.
- 523 25. Liu Y, Zhao C, Meng J, Li N, Xu Z, Liu X, et al. Galectin-3 regulates microglial activation and promotes
524 inflammation through TLR4/MyD88/NF- κ B in experimental autoimmune uveitis. *Clin Immunol*. 2022
525 Mar;236:108939.
- 526 26. Matas Pérez E, Valdivieso Shephard JL, Bravo García-Morato M, Robles Marhuenda Á, Martínez-
527 Ojinaga Nodal E, Prieto Bozano G, et al. Variants in CASP10, a diagnostic challenge: Single center
528 experience and review of the literature. *Clin Immunol*. 2021 Sep;230:108812.
- 529 27. Sakitani K, Hirata Y, Hayakawa Y, Serizawa T, Nakata W, Takahashi R, et al. Role of Interleukin-32 in
530 *Helicobacter pylori*-Induced Gastric Inflammation. *Infect Immun*. 2012 Nov;80(11):3795–803.
- 531 28. Hwang I, Gottlieb PD. Bop: a new T-cell-restricted gene located upstream of and opposite to mouse
532 CD8b. *Immunogenetics*. 1995;42(5):353–61.
- 533 29. Ma X, Wen G, Zhao Z, Lu L, Li T, Gao N, et al. Alternations in the human skin, gut and vaginal
534 microbiomes in perimenopausal or postmenopausal Vulvar lichen sclerosus. *Sci Rep*. 2024 Apr
535 10;14(1):8429.
- 536 30. Brandt K, Barrangou R. Using glycolysis enzyme sequences to inform *Lactobacillus* phylogeny.
537 *Microb Genomics*. 2018 Jun 1;4(6).
- 538 31. Adapen C, Réot L, Menu E. Role of the human vaginal microbiota in the regulation of inflammation
539 and sexually transmitted infection acquisition: Contribution of the non-human primate model to a
540 better understanding? *Front Reprod Heal*. 2022 Dec 6;4.
- 541 32. Machado A, Cerca N. Influence of Biofilm Formation by *Gardnerella vaginalis* and Other Anaerobes
542 on Bacterial Vaginosis. *J Infect Dis*. 2015 Dec 15;212(12):1856–61.
- 543 33. Cerca N, Jefferson KK, Oliveira R, Pier GB, Azeredo J. Comparative Antibody-Mediated Phagocytosis
544 of *Staphylococcus epidermidis* Cells Grown in a Biofilm or in the Planktonic State. *Infect Immun*.
545 2006 Aug;74(8):4849–55.

- 546 34. Xie Z, Thompson A, Sobue T, Kashleva H, Xu H, Vasilakos J, et al. *Candida albicans* Biofilms Do Not
547 Trigger Reactive Oxygen Species and Evade Neutrophil Killing. *J Infect Dis*. 2012 Dec
548 15;206(12):1936–45.
- 549 35. Cerca N, Martins S, Cerca F, Jefferson KK, Pier GB, Oliveira R, et al. Comparative assessment of
550 antibiotic susceptibility of coagulase-negative staphylococci in biofilm versus planktonic culture as
551 assessed by bacterial enumeration or rapid XTT colorimetry. *J Antimicrob Chemother*. 2005 Aug
552 1;56(2):331–6.
- 553 36. Tobudic S, Kratzer C, Lassnigg A, Presterl E. Antifungal susceptibility of *Candida albicans* in biofilms.
554 *Mycoses*. 2012 May 28;55(3):199–204.
- 555 37. Antonio MAD, Meyn LA, Murray PJ, Busse B, Hillier SL. Vaginal Colonization by Probiotic
556 *Lactobacillus crispatus* CTV-05 Is Decreased by Sexual Activity and Endogenous Lactobacilli. *J Infect*
557 *Dis*. 2009 May 15;199(10):1506–13.
- 558 38. Mirmonsef P, Hotton AL, Gilbert D, Burgad D, Landay A, Weber KM, et al. Free Glycogen in Vaginal
559 Fluids Is Associated with *Lactobacillus* Colonization and Low Vaginal pH. *PLoS One*. 2014 Jul
560 17;9(7):e102467.
- 561 39. Farage MA, Miller KW, Sobel JD. Dynamics of the Vaginal Ecosystem—Hormonal Influences. *Infect*
562 *Dis Res Treat*. 2010 Jan 20;3:IDRT.S3903.
- 563 40. Alcendor DJ. Evaluation of Health Disparity in Bacterial Vaginosis and the Implications for
564 HIV-1 Acquisition in African American Women. *Am J Reprod Immunol*. 2016 Aug
565 4;76(2):99–107.
- 566
- 567

Figures

Figure 1: Trial flow diagram.

Illustrated is a flow diagram of recipient participants within the VMT RCT study. Initially, potential participants underwent screening for microbiota composition and tests for various infections and conditions. Upon passing these screenings, they were randomly assigned in a 3:1 ratio to either the VMT or placebo intervention groups.




Figure 2: Bacterial composition in recipients.

A: Stacked bar chart describing the microbiome composition of selected taxa at all visits. Flow cytometry (FC) and open-label pre-treatment (PT) participants indicated in top row for intervention (VMT) and placebo groups.

B: Stacked bar chart showing the most dominant taxa for participants at baseline in the RCT study.





Figure 3: Treatment response rate in the RCT study.

A: Kaplan-Meier estimates of conversion to eubiosis at any visit after the first dosing.

Tick marks on the Kaplan-Meier curves represent individuals censored at the time of conversion to eubiosis or the last assessment. HR = Hazard Ratio.

B: Percentages for primary outcome incl. dropouts.



b

Primary outcome (RCT study)	Converted	Not converted	Drop out*	Total
Active group, n (% of group)	7 (19%)	28 (76%)	2 (5%)	37 (100%)
Placebo group, n (% of group)	3 (25%)	8 (67%)	1 (8%)	12 (100%)
Total, n (% of all)	10 (20%)	36 (73%)	3 (6%)	49 (100%)

Figure 4: Single Nucleotide Variant (SNV) analysis of engraftment in RCT study

To the left: Dendrograms of Manhattan distances between SNV profiles generated from metagenomic sequencing of CVS samples. The text in bold indicates samples from the donor-recipient pair with low genetic distance indicating successful donor engraftment. All other samples containing *L. crispatus* (A) and *L. iners* (B) are shown in grey and have larger genetic distances compared to the donor-recipient pair.

To the right: Overview of microbiome composition in the two participants who converted their microbiome with donor strain engraftment. Sampling date (x-axis) and relative taxa abundance of the taxa (y-axis).




Figure 5: Results from open-label antiseptic pretreatment study

A: Odds ratios are for the for comparison of antiseptic treatment + VMT compared to either saline or antiseptic.


B: Dendrogram of Manhattan distances between Single Nucleotide Variant (SNV) profiles generated from metagenomic sequencing of CVS samples. The colored text indicates samples from the donor-recipient pair with low genetic distance indicating successful donor engraftment.

C: Effects estimates of differentially expressed genes in CVS between converted (n=4) vs. non-converted (n=5) participants in the antiseptic + VMT group after treatment adjusted for pre-treatment expression. Up and down-regulated genes are in red and blue respectively

a

Outcome (Pretreatment trial)	Converted	Not converted	Total	
VMT + Antiseptic + Saline	5 (50%)	5 (50%)	10 (100%)	
VMT + Saline	0 (0%)	10 (100%)	10 (100%)	0.0065
Antiseptic + Saline	0 (0%)	7 (100%)	7 (100%)	
				Odds ratio
VMT + Antiseptic vs. VMT only				21 (1.83-2956)
VMT + Antiseptic vs. Antiseptic only				15 (1.25-2131)
VMT only vs. Antiseptic only				1 (0-139)
				p-value
				0.011
				0.03
				0.87

b



c




Table 1
Demographic data on VMT and placebo-group. Data
are n (%), mean (SD).

		VMT (n=37)	Placebo (n= 12)
Age (mean, SD)		25.5, +/- 3.8	26.8, +/- 4.9
BMI (mean , SD)		23.6, +/- 5.1	22.0 +/- 2.1
Smoker Number (%)	Current	2 (5.4%)	0 (0%)
	Former	12 (35.1%)	4 (33.3%)
Education Number (%)	High School	36 (97.3%)	11 (91.7%)
	Bachelor's degree	6 (16.2%)	4 (33.3%)
	Master	5 (13.5%)	2 (16.7%)
Regular menstrual cycle, Number (%)	Yes	33 (89.2%)	10 (83.3%)
	No	4 (10.8%)	2 (16.7%)
Type of Birth Control, Number (%)	Hormonal	18 (48.6%)	5 (41.7%)
	IUD	12 (32.4%)	3 (25.0%)
	Combined Oral Contraceptive	6 (16.2%)	2 (16.7%)
	Non-Hormonal	19 (51.4%)	7 (58.3%)
	Cobber IUD	4 (10.8%)	1 (8.3%)
	Condom	5 (13.5%)	5 (41.7%)
	No Contraception	10 (27.0%)	1 (8.2%)
Vaginal Symptoms, Number (%)	Yes	29(78.4%)	6 (50.0%)
	Increased amount of discharge	16(55.0%)	5(83.3%)
	Greenish coloured discharge	0	0
	Whitish coloured discharged	5(17.2%)	1(16.7%)
	Nuisance from vaginal odor	24(82.8%)	4(66.7%)
	Stinging feeling	2(6.9%)	0
	Itching feeling	0	1(16.7%)
	Other	2(6.9%)	1(16.7%)
	No	8(21.6%)	6(50.0%)
Diagnosed with endometriosis		0	0
Diagnosed with PCOS		0	0
Pregnancy loss		0	0
Diagnosed with infertility		0	0
HPV	HPV positive	7(18.9%)	0
	* unknown	4(10.8%)	0
Cell changes	Yes	6(16.2%)	1(8.3%)
	* unknown	3(8.1%)	1(8.3%)
Former gynecological infections	Yes	16(43.2%)	4(33.3%)
	Chlamydia	9(24.3%)	4(33.3%)
	Gonorrhoea	0	0
	BV	4(10.8%)	2(16.7%)
	Trichomonas	0	0
	Teast	11(68.8%)	3(75.0%)
	Mycoplasma	0	0
	Herpes	1(6.3%)	0
	Genital warts	0	0
	Syphilis	0	0
	other	0	0
	No	11(29.7%)	6(50.0%)
	* unknown	10(27.0%)	2(16.7%)
Vaginal douching within the last 3 months		3(8.1%)	0
In a heterosexual relationship	Yes	12(32.4%)	7(58.3%)
	No	25(67.6%)	5(41.7%)
Number of malesexual partners with the last 3 months	0	9(24.3%)	0
	1	18(48.7%)	8(66.7%)
	2	5(13.5%)	2(16.7%)
	>2	5(13.5%)	2(16.7%)
Number of heterosexual partners in life so far	1 to 10	10(27.0%)	3(25.0%)
	11 to 20	11(29.7%)	3(25.0%)
	21-30	9(24.3%)	3(25.0%)
	31+	7(18.9%)	3(25.0%)

